Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development

Akdis, 2012, Therapies for allergic inflammation: refining strategies to induce tolerance, Nat Med, 18, 736, 10.1038/nm.2754

Durham, 2010, Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet, J Allergy Clin Immunol, 125, 131, 10.1016/j.jaci.2009.10.035

Akdis, 2009, Therapeutic manipulation of immune tolerance in allergic disease, Nat Rev Drug Discov, 8, 645, 10.1038/nrd2653

Burks, 2013, Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report, J Allergy Clin Immunol, 131, 1288, 10.1016/j.jaci.2013.01.049

Agache, 2012, Untangling asthma phenotypes and endotypes, Allergy, 67, 835, 10.1111/j.1398-9995.2012.02832.x

Akdis, 2013, Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology, J Allergy Clin Immunol, 131, 1479, 10.1016/j.jaci.2013.02.036

Lotvall, 2011, Asthma endo-types: a new approach to classification of disease entities within the asthma syndrome, J Allergy Clin Immunol, 127, 355, 10.1016/j.jaci.2010.11.037

Bousquet, 2012, Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs, J Allergy Clin Immunol, 130, 1049, 10.1016/j.jaci.2012.07.053

Meiler, 2008, In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure, J Exp Med, 205, 2887, 10.1084/jem.20080193

Platts-Mills, 2011, Allergens and their role in the allergic immune response, Immunol Rev, 242, 51, 10.1111/j.1600-065X.2011.01021.x

Rebane, 2013, MicroRNAs: Essential players in the regulation of inflammation, J Allergy Clin Immunol, 132, 15, 10.1016/j.jaci.2013.04.011

Soyka, 2012, Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN-gamma and IL-4, J Allergy Clin Immunol, 130, 1087, 10.1016/j.jaci.2012.05.052

Papadopoulos, 2012, Research needs in allergy: an EAACI position paper, in collaboration with EFA, Clin Transl Allergy, 2, 21, 10.1186/2045-7022-2-21

Jutel, 1996, Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils, Clin Exp Allergy, 26, 1112, 10.1111/j.1365-2222.1996.tb00496.x

Jutel, 1995, Ultra rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate, Clin Exp Allergy, 25, 1205, 10.1111/j.1365-2222.1995.tb03044.x

Romano, 2011, Diagnosis and management of drug hypersensitivity reactions, J Allergy Clin Immunol, 127, S67, 10.1016/j.jaci.2010.11.047

Jutel, 2009, Histamine, histamine receptors and their role in immune pathology, Clin Exp Allergy, 39, 1786, 10.1111/j.1365-2222.2009.03374.x

O'Mahony, 2011, Regulation of the immune response and inflammation by histamine and hista-mine receptors, J Allergy Clin Immunol, 128, 1153, 10.1016/j.jaci.2011.06.051

Novak, 2012, Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2, J Allergy Clin Immunol, 130, 1153, 10.1016/j.jaci.2012.04.039

Eberlein-Konig, 1995, Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization, Clin Exp Allergy, 25, 704, 10.1111/j.1365-2222.1995.tb00007.x

Plewako, 2006, Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy, Int Arch Allergy Immunol, 141, 346, 10.1159/000095461

Akdis, 1998, Role of interleukin 10 in specific immunotherapy, J Clin Invest, 102, 98, 10.1172/JCI2250

Jutel, 2003, IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy, Eur J Immunol, 33, 1205, 10.1002/eji.200322919

Soyer, 2013, Mechanisms of peripheral tolerance to allergens, Allergy, 68, 161, 10.1111/all.12085

Pepper, 2011, Origins of CD4(+) effector and central memory T cells, Nat Immunol, 12, 467, 10.1038/ni.2038

Kaczorowski, 2013, Human T regulatory cells: on the way to cognition, Arch Immunol Ther Exp (Warsz), 61, 229, 10.1007/s00005-013-0217-2

Radulovic, 2008, Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa, J Allergy Clin Immunol, 121, 1467, 10.1016/j.jaci.2008.03.013

Ling, 2004, Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease, Lancet, 363, 608, 10.1016/S0140-6736(04)15592-X

Akdis, 2004, Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and Thelper 2 cells, J Exp Med, 199, 1567, 10.1084/jem.20032058

Aslam, 2010, Tracking antigen-specific T-cells during clinical tolerance induction in humans, PLoS One, 5, e11028, 10.1371/journal.pone.0011028

Campbell, 2009, Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression, J Exp Med, 206, 1535, 10.1084/jem.20082901

Chung, 2011, Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions, Nat Med, 17, 983, 10.1038/nm.2426

Klunker, 2009, Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells, J Exp Med, 206, 2701, 10.1084/jem.20090596

Orihara, 2007, Circulating Foxp3+ CD4+ cell numbers in atopic patients and healthy control subjects, J Allergy Clin Immunol, 120, 960, 10.1016/j.jaci.2007.05.036

Karlsson, 2004, Allergen responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy, J Exp Med, 199, 1679, 10.1084/jem.20032121

Jartti, 2007, Association between CD4(+)CD25(high) T cells and atopy in children, J Allergy Clin Immunol, 120, 177, 10.1016/j.jaci.2007.03.008

Mobs, 2012, Birch pollen immuno-therapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies, J Allergy Clin Immunol, 130, 1108, 10.1016/j.jaci.2012.07.056

Kucuksezer, 2013, Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood, J Allergy Clin Immunol, 131, 875, 10.1016/j.jaci.2012.10.051

Akdis, 1996, Epitope specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro, J Clin Invest, 98, 1676, 10.1172/JCI118963

Van Ree, 1997, Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy, Clin Exp Allergy, 27, 68, 10.1046/j.1365-2222.1997.d01-416.x

Jutel, 2005, Allergen-specific immunotherapy with recombinant grass pollen allergens, J Allergy Clin Immunol, 116, 608, 10.1016/j.jaci.2005.06.004

Meiler, 2008, Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors, Allergy, 63, 1455, 10.1111/j.1398-9995.2008.01774.x

van de Veen, 2013, IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses, J Allergy Clin Immunol, 131, 1204, 10.1016/j.jaci.2013.01.014

van der Neut, 2007, Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange, Science, 317, 1554, 10.1126/science.1144603

van der Zee, 1986, Inhibition of complement activation by IgG4 antibodies, Clin Exp Immunol, 64, 415

James, 2011, Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies, J Allergy Clin Immunol, 127, 509, 10.1016/j.jaci.2010.12.1080

Radbruch, 2006, Competence and competition: the challenge of becoming a long-lived plasma cell, Nat Rev Immunol, 6, 741, 10.1038/nri1886

Pierkes, 1999, Decreased release of histamine and sulfidoleu-kotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells, J Allergy Clin Immunol, 103, 326, 10.1016/S0091-6749(99)70509-9

Gri, 2008, CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction, Immunity, 29, 771, 10.1016/j.immuni.2008.08.018

Marshall, 1996, Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells, J Clin Invest, 97, 1122, 10.1172/JCI118506

Biggs, 2010, Evidence that vitamin D(3) promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice, J Exp Med, 207, 455, 10.1084/jem.20091725

Galli, 2008, Immunomodulatory mast cells: negative, as well as positive, regulators of immunity, Nat Rev Immunol, 8, 478, 10.1038/nri2327

Turner, 2011, CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2 granulomatous pathology caused by schistosome infection, PLoS Negl Trop Dis, 5, e1269, 10.1371/journal.pntd.0001269

Plewako, 2008, A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa, Clin Exp Allergy, 38, 1124, 10.1111/j.1365-2222.2008.03005.x

Akdis, 2001, Bypassing IgE and targeting T cells for specific immunotherapy of allergy, Trends Immunol, 22, 175, 10.1016/S1471-4906(01)01862-2

Kussebi, 2005, A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy, J Allergy Clin Immunol, 115, 323, 10.1016/j.jaci.2004.11.041

Karamloo, 2005, Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epi-topes, Eur J Immunol, 35, 3268, 10.1002/eji.200425522

Niederberger, 2004, Vaccination with genetically engineered allergens prevents progression of allergic disease, Proc Natl Acad Sci USA, 101, 14677, 10.1073/pnas.0404735101

Norman, 1996, Treatment of cat allergy with T cell reactive peptides, Am J Respir Crit Care Med, 154, 1623, 10.1164/ajrccm.154.6.8970345

Müller, 1998, Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients, J Allergy Clin Immunol, 101, 747, 10.1016/S0091-6749(98)70402-6

Worm, 2011, Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy, J Allergy Clin Immunol, 127, 89, 10.1016/j.jaci.2010.11.029

Pree, 2007, Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man, J Immunol, 179, 5309, 10.4049/jimmunol.179.8.5309

Jutel, 2012, Recombinant allergens: the present and the future, Hum Vaccin Immunother, 8, 1534, 10.4161/hv.22064

Creticos, 2006, Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis, N Engl J Med, 355, 1445, 10.1056/NEJMoa052916

Kundig, 2006, Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults, J Allergy Clin Immunol, 117, 1470, 10.1016/j.jaci.2006.01.040

Rosewich, 2010, Tolerance induction after specific immunotherapy with pollen aller-goids adjuvanted by monophosphoryl lipid A in children, Clin Exp Immunol, 160, 403, 10.1111/j.1365-2249.2010.04106.x

Wilson, 2005, Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis, Allergy, 60, 4, 10.1111/j.1398-9995.2005.00699.x

Bufe, 2009, Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy, J Allergy Clin Immunol, 123, 167, 10.1016/j.jaci.2008.10.044

Scadding, 2010, Clin Exp Allergy, 40, 598, 10.1111/j.1365-2222.2010.03462.x

Allam, 2008, Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells, J Allergy Clin Immunol, 121, 368, 10.1016/j.jaci.2007.09.045

Palomares, 2012, Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance, JAllergy Clin Immunol, 129, 510, 10.1016/j.jaci.2011.09.031

Senti, 2012, Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study, J Allergy Clin Immunol, 129, 128, 10.1016/j.jaci.2011.08.036

Senti, 2008, Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial, Proc Natl Acad Sci USA, 105, 17908, 10.1073/pnas.0803725105

Zhu, 2002, A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation, Nat Med, 8, 518, 10.1038/nm0502-518

Zhu, 2005, A chimeric human-cat fusion protein blocks cat-induced allergy, Nat Med, 11, 446, 10.1038/nm1219

Crameri, 2009, Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy, Curr Opin Allergy Clin Immunol, 9, 568, 10.1097/ACI.0b013e3283310fdf

Senti, 2012, Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections, J Allergy Clin Immunol, 129, 1290, 10.1016/j.jaci.2012.02.026

Massanari, 2010, Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma, J Allergy Clin Immunol, 125, 383, 10.1016/j.jaci.2009.11.022

Klunker, 2007, Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding, J Allergy Clin Immunol, 120, 688, 10.1016/j.jaci.2007.05.034

Asturias, 2009, Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy, Clin Exp Allergy, 39, 1088, 10.1111/j.1365-2222.2009.03264.x

Thunberg, 2009, Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice, Allergy, 64, 919, 10.1111/j.1398-9995.2008.01905.x

Niespodziana, 2011, A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS, J Allergy Clin Immunol, 127, 1562, 10.1016/j.jaci.2011.02.004